Krishnan Krish S sold $96K of KRYS
Krishnan Krish S (President and CEO) sold 320 shares of Krystal Biotech, Inc. (KRYS) at $300.75 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure can slightly influence sentiment, but 10b5-1 pre-arranged selling usually limits the informational content about near-term fundamentals.
Market read
Traders may monitor for follow-on insider activity, but this single small 10b5-1 sale is unlikely to drive a major repricing by itself.
What to watch
The market may overreact to insider selling; the disclosed post-transaction holdings and plan structure matter more than the headline dollar amount.
Background
This is an SEC Form 4 insider transaction for Krystal Biotech, Inc., reporting an open-market sale by the CEO/10% owner.
Ticker impact
Krystal Biotech CEO/10% owner sold 320 shares in an open-market transaction disclosed via SEC Form 4 on June 4.
Likely limited near-term impact; any reaction should be small unless accompanied by other fundamental news.
Form 4 shows a small value sale (~$96k) under a pre-arranged 10b5-1 plan, which typically dampens market inference about new information.
Market effects
No direct sector read-through; this is company-specific insider activity without new clinical/regulatory catalysts.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the insider transaction disclosure (CEO/10% owner sale).
- insiderKrishnan Krish S
President and CEO; sold 320 shares at $300.75 on June 4 under a 10b5-1 plan.
